» Articles » PMID: 18046334

The Interplay Between MYC and HIF in Cancer

Overview
Journal Nat Rev Cancer
Specialty Oncology
Date 2007 Nov 30
PMID 18046334
Citations 305
Authors
Affiliations
Soon will be listed here.
Abstract

The interaction of MYC and hypoxia inducible factors (HIFs) under physiological, non-tumorigenic conditions provides insights into normal homeostatic cellular responses to low oxygen levels (hypoxia). Many tumours contain genetic alterations, such as MYC activation, that can collaborate with HIF to confer metabolic advantages to tumour cells, which tend to exist in a hypoxic microenvironment. This Perspective emphasizes the differences between the transcriptional network that operates under normal homeostatic conditions and the network in a tumorigenic milieu.

Citing Articles

Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.

Espin R, Medina-Jover F, Siguenza-Andrade J, Farran-Matas S, Mateo F, Figueras A NAR Cancer. 2025; 7(1):zcaf007.

PMID: 40061566 PMC: 11886861. DOI: 10.1093/narcan/zcaf007.


Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment.

Chia M, Bulat F, Gaunt A, Ros S, Wright A, Sawle A Oncogene. 2024; 44(9):563-574.

PMID: 39639170 PMC: 11850285. DOI: 10.1038/s41388-024-03231-w.


Tumor energy metabolism: implications for therapeutic targets.

Hu Y, Liu W, Fang W, Dong Y, Zhang H, Luo Q Mol Biomed. 2024; 5(1):63.

PMID: 39609317 PMC: 11604893. DOI: 10.1186/s43556-024-00229-4.


Intratumoral microbiota: a new force in the development and treatment of esophageal cancer.

Jing T, Tang D Clin Transl Oncol. 2024; .

PMID: 39455494 DOI: 10.1007/s12094-024-03757-1.


Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges.

Ubanako P, Mirza S, Ruff P, Penny C Front Mol Biosci. 2024; 11:1447953.

PMID: 39355533 PMC: 11442288. DOI: 10.3389/fmolb.2024.1447953.